4.73-【2.2/3-(1.8+2.63)】

This document describes the security content of Safari 3.2.2 for Windows.
For the protection of our customers, Apple does not disclose, discuss, or confirm security issues until a full investigation has occurred and any necessary patches or releases are available. To learn more about Apple Product Security, see the
For information about the Apple Product Security PGP Key, see &.&
Where possible,
are used to reference the vulnerabilities for further information.
To learn about other Security Updates, see &.&
This article has been archived and is no longer updated by Apple.
Safari 3.2.2 for Windows
CVE-ID: CVE-
Available for: Windows XP or Vista
Impact: Accessing a maliciously crafted feed: URL may lead to arbitrary code execution
Description: Multiple input validation issues exist in Safari's handling of feed: URLs. The issues allow execution of arbitrary JavaScript in the local security zone. This update addresses the issues through improved handling of embedded JavaScript within feed: URLs. These issues do not affect Mac OS X systems that have applied Security Update . Credit to Clint Ruoho of Laconic Security, Billy Rios of Microsoft, and Brian Mastenbrook for reporting these issues.
Important: Information about products not manufactured by Apple is provided for information purposes only and does not constitute Apple&s recommendation or endorsement. Please
for additional information.
Thanks - please tell us how to help you better.
One Moment Please
Thanks for your feedback.
Additional Product Support Information
Start a Discussion
in Apple Support CommunitiesThe selective alpha7 nicotinic acetylcholine receptor agonist PNU-2...
- PubMed - NCBI
The NCBI web site requires JavaScript to function.
FormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListChoose DestinationFileClipboardCollectionsE-mailOrderMy BibliographyCitation managerFormatSummary (text)Abstract (text)MEDLINEXMLPMID ListCSVCreate File1 selected item: FormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListMeSH and Other DataE-mailSubjectAdditional textE-mailAdd to ClipboardAdd to CollectionsOrder articlesAdd to My BibliographyGenerate a file for use with external citation management software.Create File
):1213-22. Epub
2004 Nov 2.The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.1, , , , , , .1Department of Neuroscience, Pfizer Global Research and Development, Eastern Point Rd., Groton, CT 06340, USA. mihaly.AbstractSchizophrenic patients are thought to have an impaired ability to process sensory information. This deficit leads to disrupted auditory gating measured electrophysiologically as a reduced suppression of the second of paired auditoryevoked responses (P50) and is proposed to be associated with decreased function and/or expression of the homomeric alpha7 nicotinic acetylcholine receptor (nAChR). Here, we provide evidence that N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride (PNU-282987), a novel selective agonist of the alpha7 nAChR, evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity when applied to hippocampal slices. Amphetamine-induced sensory gating deficit, determined by auditory-evoked potentials in hippocampal CA3 region, was restored by systemic administration of PNU-282987 in chloral hydrate-anesthetized rats. Auditory gating of rat reticular thalamic neurons was also disr however, PNU-282987 normalized gating deficit only in a subset of tested neurons (6 of 11). Furthermore, PNU-282987 improved the inherent hippocampal gating deficit occurring in a subpopulation of anesthetized rats, and enhanced amphetamine-induced hippocampal oscillation. We propose that the alpha7 nAChR agonist PNU-282987, via modulating/enhancing hippocampal GABAergic neurotransmission, improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia.PMID:
[PubMed - indexed for MEDLINE]
Free full textMeSH TermsSubstancesFull Text SourcesOther Literature Sources
Supplemental Content
External link. Please review our .

我要回帖

更多关于 1.8 2.2的床 的文章

 

随机推荐